Tvardi Therapeutics, Inc. (TVRD)
(Delayed Data from NSDQ)
$7.00 USD
+0.31 (4.63%)
Updated Oct 14, 2025 04:00 PM ET
After-Market: $6.81 -0.19 (-2.71%) 7:54 PM ET
3-Hold of 5 3
F Value A Growth A Momentum C VGM
Fundamental Charts
About Return on Equity (TTM)
Tvardi Therapeutics, Inc.'s return on equity, or ROE, is -565.83% compared to the ROE of the Medical - Biomedical and Genetics industry of -65.07%. While this shows that TVRD has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
TVRD 7.00 +0.31(4.63%)
Will TVRD be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for TVRD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TVRD
TVRD Stock Plunges 84% After Phase II Fibrosis Study Misses Key Goals
TVRD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for TVRD
Tivardi downgraded at Raymond James following TTI-101 trial failure
Tvardi Therapeutics (TVRD) Downgraded by Raymond James | TVRD Stock News
Is TVRD poised for gains? Slingshot Bullish shows up after crashing 83.92%
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Tvardi downgraded to Market Perform from Outperform at Raymond James